RIGL Q1 2023 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+55.8% YoY

Gross Profit

$25M96.3% margin

Operating Income

-$13M-48.8% margin

Net Income

-$14M-51.9% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

-49.2%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$19M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$124M

Total Liabilities

$148M

Stockholders' Equity

-$24M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$17M	+55.8%
Gross Profit	$25M	$17M	+51.0%
Operating Income	-$13M	-$26M	+51.5%
Net Income	-$14M	-$27M	+50.7%

Revenue Segments

Gross product sales

$33M67%

Product sales, net

$24M48%

Contract revenues from collaborations

$2M5%

Discounts and allowances

-$9M-19%